Nab-paclitaxel plus capecitabine as first-line treatment for advanced biliary tract cancers: An open-label, non-randomized, phase II clinical trial

Table 1 Basic demographic characteristics, n (%)

Characteristic	Total (n = 44)
Age, years (median, IQR)	64.00 (35.00, 76.00)
Sex
Male	18 (40.91)
Female	26 (59.09)
ECOG performance
0	25 (56.82)
1	19 (43.18)
Tumor subtype
Gallbladder cancer	20 (45.45)
Intrahepatic cholangiocarcinoma	11 (25.00)
Extrahepatic cholangiocarcinoma	13 (29.55)
Number of metastatic sites
No metastasis	3 (6.82)
Single	21 (47.73)
Multiple	20 (45.45)
Metastatic sites
Liver	20 (45.45)
Lung	5 (11.36)
Peritoneum	9 (20.45)
Previous antitumor therapy
Radical resection	26 (59.09)
Adjuvant systemic therapy	7 (15.91)
Stage
III	1 (2.27)
IV	40 (90.91)
Uncertain	3 (6.82)
Baseline CA199
< 37 U/mL	16 (36.36)
≥ 37 U/mL	28 (63.64)

ECOG: Eastern Cooperative Oncology Group; CA199: Carbohydrate antigen 199; IQR: Interquartile range.